Edition:
India

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

733.20INR
2:30pm IST
Change (% chg)

Rs-2.50 (-0.34%)
Prev Close
Rs735.70
Open
Rs736.50
Day's High
Rs740.60
Day's Low
Rs730.65
Volume
1,418,762
Avg. Vol
3,949,848
52-wk High
Rs830.45
52-wk Low
Rs527.00

Chart for

About

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system,... (more)

Overall

Beta: 0.84
Market Cap(Mil.): Rs437,068.31
Shares Outstanding(Mil.): 585.88
Dividend: 1.25
Yield (%): 0.52

Financials

  ARBN.NS Industry Sector
P/E (TTM): 19.51 31.13 34.40
EPS (TTM): 38.23 -- --
ROI: -- 15.55 14.96
ROE: -- 16.92 16.53

BUZZ-India's Aurobindo Pharma falls; report says co faces U.S. class action lawsuit

** Shares of drugmaker Aurobindo Pharma Ltd fall as much as 4 pct to 764.55 rupees, their lowest since Nov 13

06 Dec 2018

MEDIA-India's Aurobindo Pharma faces US suit over carcinogenic elements in blood pressure drug - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

06 Dec 2018

Aurobindo Pharma second-quarter profit falls nearly 22 percent

Aurobindo Pharma Ltd, India's second-largest drugmaker by market capitalisation, posted a 21.7 percent fall in its second-quarter profit on Monday, hurt by higher expenses, but beat analysts' estimates.

12 Nov 2018

India's Aurobindo Pharma Q2 profit falls nearly 22 pct

Nov 12 Aurobindo Pharma Ltd, India's second-largest drugmaker by market capitalisation, posted a 21.7 percent fall in its second-quarter profit on Monday, hurt by higher expenses, but beat analysts' estimates.

12 Nov 2018

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

ZURICH/BENGALURU New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

06 Sep 2018

UPDATE 3-Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

* Deal to result in $70 mln impairment for Novartis (Adds related content, detail about impairment in third graf, updates shares)

06 Sep 2018

Novartis sells U.S. generics assets to bargain-hunting Aurobindo Pharma

ZURICH/BENGALURU New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

06 Sep 2018

BUZZ-India's Aurobindo Pharma rises, co to buy parts of Sandoz U.S. for $900 mln

** Aurobindo Pharma Ltd rises as much as 3.6 pct to 722 rupees

06 Sep 2018

Novartis sells parts of Sandoz US to India's Aurobindo for $900 mln

Sept 6 Novartis AG said on Thursday it would sell the dermatology and generic U.S. oral solids portfolios of Sandoz U.S. to India's Aurobindo Pharma Ltd for $900 million, as the Swiss drugmaker looks to focus on higher growth areas.

06 Sep 2018

Aurobindo Pharma first-quarter profit misses estimates

Aurobindo Pharma Ltd reported a 12 percent fall in quarterly profit on Thursday and missed analysts' expectations, hurt by higher expenses.

09 Aug 2018

Earnings vs. Estimates